TABLE 2. Demographic and clinical features of participants based on bile acid group.
| Six‐month post‐KP bile acid group | p | ||
|---|---|---|---|
| ≤40 μmol/L (n = 43) | >40 μmol/L (n = 94) | ||
| Sex, % (n/N) | |||
| Female | 44.2% (19 of 43) | 55.3% (52 of 94) | 0.270 |
| Male | 55.8% (24 of 43) | 44.7% (42 of 94) | |
| Race, % (n/N) | |||
| Black | 9.5% (4 of 42) | 10.9% (10 of 92) | 0.769 |
| Multiraciala | 9.5% (4 of 42) | 16.3% (15 of 92) | |
| White | 64.3% (27 of 42) | 53.3% (49 of 92) | |
| Otherb | 7.1% (3 of 42) | 10.9% (10 of 92) | |
| Hispanic, % (n/N) | 25.6% (11 of 43) | 36.2% (34 of 94) | 0.245 |
| BASM, % (n/N) | 9.3% (4 of 43) | 8.5% (8 of 94) | 1.000 |
| KP age (days), median (range) [n] | 57 (17, 117) [43] | 69 (25, 133) [94] | 0.009 |
| START arm, % (n/N) | |||
| Placebo | 28.6% (4 of 14) | 54.3% (19 of 35) | 0.125 |
| Steroid | 71.4% (10 of 14) | 45.7% (16 of 35) | |
| Ursodeoxycholic acid use, % (n/N) | 58.1% (25 of 43) | 63% (58 of 92) | 0.705 |
| History of cholangitis, % (n/N) | 41.9% (18 of 43) | 27.7% (26 of 94) | 0.116 |
| History of fracture, % (n/N) | 0% (0 of 43) | 1.1% (1 of 94) | 1.000 |
| Ascites, % (n/N) | 11.6% (5 of 43) | 14.9% (14 of 94) | 0.791 |
| History of GI bleed, % (n/N) | 0% (0 of 43) | 5.3% (5 of 94) | 0.325 |
| CEPH, % (n/N) | 37.2% (16 of 43) | 63.8% (60 of 94) | 0.005 |
Abbreviation: GI, gastrointestinal.
a
More than 1 of American Indian or Alaska Native, Asian, Black or African American, Native Hawaiian or Other Pacific Islander, White, or other.
b
American Indian or Alaska Native, Native Hawaiian or other Pacific Islander, or other.